Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemcitabine in cervical cancer.

David G Mutch1, Jeffrey D Bloss

  • 1Department of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA. mutchd@msnotes.wustl.edu

Gynecologic Oncology
|August 21, 2003
PubMed
Summary

Gemcitabine shows promise for treating advanced cervical cancer, especially when combined with cisplatin or radiation therapy. Further research is ongoing to confirm its effectiveness in comparison to standard treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optical coherence tomography enables optical biopsy of endometrial tissue for early cancer detection.

Npj imaging·2026
Same author

Correction: GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.

Molecular cancer research : MCR·2026
Same author

Targeting RAD52 overcomes PARP inhibitor resistance in preclinical <i>Brca2</i>-deficient ovarian cancer model.

bioRxiv : the preprint server for biology·2025
Same author

Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol.

Gynecologic oncology·2025
Same author

Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy-Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response.

Cancer research·2025
Same author

Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc's Scholar Career Development Award and New Investigator Program.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Clinical Pharmacology

Background:

  • Recurrent and advanced cervical cancers present significant treatment challenges with high mortality rates.
  • Limited effective options exist for patients unsuitable for surgery or radiation therapy.
  • Gemcitabine's established efficacy and low toxicity in other cancers suggest potential for cervical tumors.

Purpose of the Study:

  • To review the clinical effectiveness of gemcitabine in recurrent or advanced cervical cancer.
  • To evaluate gemcitabine as a single agent and in combination therapies.
  • To assess gemcitabine's role in induction therapy and neoadjuvant chemotherapy.

Main Methods:

  • Systematic review of fifteen Phase I/II clinical trials.
  • Analysis of gemcitabine monotherapy and combination regimens with cisplatin.
  • Evaluation of data from studies involving concurrent chemoradiotherapy and neoadjuvant chemotherapy.

Main Results:

  • Single-agent gemcitabine demonstrated inferior outcomes compared to cisplatin.
  • Concurrent use of gemcitabine with cisplatin and/or radiation therapy yielded high objective response rates and prolonged survival.
  • Gemcitabine combined with cisplatin showed promise as neoadjuvant therapy.

Conclusions:

  • Gemcitabine, particularly in combination with cisplatin, appears beneficial for managing recurrent or advanced cervical cancer.
  • A Phase III trial comparing cisplatin/gemcitabine to the standard of care is planned.
  • Further investigation of gemcitabine in conjunction with radiotherapy and as neoadjuvant therapy is warranted.

Related Experiment Videos